As of 14 Oct 2026, Timberlyne Therapeutics has raised $180M across 1 verified round on record; latest: $180 million Series A led by Abingworth, Bain Capital Life Sciences and 1 other, announced 9 Jan 2025.
Timberlyne Therapeutics develops biopharmaceutical therapies for autoimmune diseases.
1 source
The source identifies San Diego in the dateline, but does not state that it is Timberlyne Therapeutics' headquarters.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $180M | 2025-01-09 | Abingworth, Bain Capital Life Sciences, Venrock Healthcare Capital Partners | No recent discussion |
1 source [ VERIFIED ] read against 1 source The source identifies San Diego in the dateline, but does not state that it is Timberlyne Therapeutics' headquarters. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: prnewswire.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 source·[ BRANDING ]logo and colour from the homepage | ||||